The power of proteasome inhibition in multiple myeloma

@article{GuerreroGarcia2018ThePO,
  title={The power of proteasome inhibition in multiple myeloma},
  author={Thomas A Guerrero-Garcia and Sara Gandolfi and Jacob P. Laubach and Teru Hideshima and Dharminder Chauhan and Constantine Mitsiades and Kenneth C. Anderson and Paul G. Richardson},
  journal={Expert Review of Proteomics},
  year={2018},
  volume={15},
  pages={1033 - 1052}
}
ABSTRACT Introduction: Proteasome inhibitors (PIs) are therapeutic backbones of multiple myeloma treatment, with PI-based therapies being standards of care throughout the treatment algorithm. Proteasome inhibition affects multiple critical signaling pathways in myeloma cells and interacts synergistically with mechanisms of action of other conventional and novel agents, resulting in substantial anti-myeloma activity and at least additive effects. Areas covered: This review summarizes the… 
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
TLDR
This review summarizes the impact of protein modifications such as ubiquitination and ubiquitin-like modifications in the biology of multiple myeloma and how it can be exploited to develop new effective therapies for multipleMyeloma.
Carfilzomib for relapsed and refractory multiple myeloma
TLDR
The once-weekly administration of carfilzomib, recently approved by the FDA in combination with dexamethasone, will lead to a lower burden for the patient and caregivers compared to the twice-weekly schemes that were routinely used until recently.
Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma
TLDR
It is demonstrated that GGSI/PI treatment can potentiate activation of the UPR and apoptotic pathway, as well as induce upregulation of markers associated with the ICD pathway.
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
TLDR
HUWE1 depletion in combination with lenalidomide resulted in synergistic anti-MM activity in both in vitro and in vivo models, and provides preclinical rationale for therapeutic strategies targeting H UWE1 in MM.
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
TLDR
PSMB6 and PSMB7 are shown to be essential for multiple myeloma cell survival, this dependency is structural and that upregulation or activating mutation of PSMB5, 6, and 7 confers proteasome inhibitor resistance, while depletion confers sensitivity.
Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
TLDR
This is the largest cross-indication review comparing RWE to CT results, aspiring to inform clinical practice and decision-making when funding hemato-oncology pharmaceuticals.
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells
TLDR
The findings suggest that the HBP may play a major role in mitochondrial fitness, driving BTZ resistance in multiple myeloma and thus representing a possible target for new drug development for BTZ-resistant patients.
DKK1 Suppresses WWP2 to Enhance Bortezomib Resistance in Multiple Myeloma via Regulating GLI2 Ubiquitination.
TLDR
DKK1 facilitates the generation of bortezomib resistance in MM via downregulating WWP2 and activating Hh pathway, and the manipulation of DKK1-WWP2-GLI2 axis might sensitize myeloma cells to proteasome inhibitors.
Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways
TLDR
Combinational targeting of MAPK signalling pathways can synergistically enhance carfilzomib‐induced cell apoptosis, suggesting that MAPK inhibitors in combination with proteasome inhibitors can serve as a novel therapeutic tool for osteosarcoma.
...
1
2
3
...

References

SHOWING 1-10 OF 178 REFERENCES
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
TLDR
Recent advancements in the understanding of the mechanism of action of proteasome inhibitors and DACi in multiple myeloma are summarized and the biological basis of their synergistic effects are examined.
Targeting the UPS as therapy in multiple myeloma
TLDR
Significant preclinical studies suggest that combination therapies can both circumvent drug resistance and reduce toxicity, and promising novel proteasome inhibitors, which are distinct from bortezomib, and exhibit equipotent anti-multiple myeloma activities, are undergoing clinical evaluation in order to improve patient outcome in multipleMyeloma.
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions
TLDR
The evidence currently available from clinical trials for the use of novel agents, particularly in the formation of triplet therapy, is examined, including data supporting the addition of the proteasome inhibitors carfilzomib and ixazomib, or the monoclonal antibodies elotuzumab or daratumumab, to a treatment backbone of lenalidomide and dexamethasone.
Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
TLDR
The characteristics of the new drugs used in RRMM are summarized with a specific focus on recent phase 3 trials of triplet combinations in this setting and the rationale behind the selection of one regimen over another.
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
TLDR
The combined anti-MM activity of marizomib and pomalidomide is examined using in vitro models of MM and clinical benefit, such as improvement in survival or symptoms, has not been verified.
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
TLDR
MLN9708 has a shorter proteasome dissociation half-life and improved pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib, and analysis of 20S proteasomesome inhibition and markers of the unfolded protein response confirmed that MLN 9708 has greater pharmacodynamic effects in tissues than bortzomib.
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
TLDR
This review details the mechanisms of HSF1 regulation and discusses leveraging that regulation to enhance PI activity and eliminate the cytoprotective heat-shock response that protects myeloma cells from proteasome inhibition.
Novel strategies to target the ubiquitin proteasome system in multiple myeloma
TLDR
A review of different components of the ubiquitin proteasome system (UPS) that play an important role in different cellular processes by targeted destruction of proteins in multiple myeloma to reduce side effects and overcome resistance.
...
1
2
3
4
5
...